Patents by Inventor Thomas Charles Boone

Thomas Charles Boone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against analogs of brain-derived neurotrophic factor
    Patent number: 6500429
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: December 31, 2002
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Integrin/adhesion antagonists
    Publication number: 20020168363
    Abstract: The present invention concerns fusion of half-life extending vehicles, preferably Fc domains, with peptide sequences that act as antagonists of integrins, selectins, cell adhesion molecules, or their respective receptors. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide may be an existing peptide or a peptide selected by phage display, E. coli display, ribosome display, RNA-peptide screening, chemical-peptide screening, or other methods.
    Type: Application
    Filed: April 23, 2001
    Publication date: November 14, 2002
    Applicant: Amgen Inc.
    Inventors: Ulrich Feige, Tadahiko Kohno, David Lee Lacey, Thomas Charles Boone
  • Analogs of NT-3
    Patent number: 6468970
    Abstract: The in vivo circulating life and/or absorption of Neurophic Factor-3 (NT-3) is increased by generating certain substitution analogs of the native protein sequence that result in a lower isoelectric point and charge in relation to NT-3 of native sequence.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: October 22, 2002
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Substitution analogs of NT-3
    Publication number: 20020052488
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Application
    Filed: June 1, 2001
    Publication date: May 2, 2002
    Applicant: AMGEN INC.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Analogs of cationic proteins
    Publication number: 20020010135
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Application
    Filed: December 19, 2000
    Publication date: January 24, 2002
    Applicant: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Fibroblast growth factor receptor-like molecules and uses thereof
    Publication number: 20020009776
    Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.
    Type: Application
    Filed: March 22, 2001
    Publication date: January 24, 2002
    Applicant: Amgen, Inc.
    Inventors: Christiaan M. Saris, Sharon X. Mu, Min Xia, Thomas Charles Boone, Todd Covey
  • Antibodies against analogs of brain-derived neurotrophic factor
    Publication number: 20010027179
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Application
    Filed: December 19, 2000
    Publication date: October 4, 2001
    Applicant: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young
  • Analogs of NT-3
    Patent number: 6271364
    Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Ellen Ngoi Yin Cheung, Thomas Charles Boone, Susan Irene Hershenson, John David Young
  • Analogs of cationic proteins
    Patent number: 6211150
    Abstract: The in vivo circulating life and/or absorption of the cationic therapeutic protein BDNF can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: April 3, 2001
    Assignee: Amgen Inc.
    Inventors: Thomas Charles Boone, Ellen Ngoi Yin Cheung, Susan Irene Hershenson, John David Young